Showing results (21-30 of 48) with videos related to
Sort By:
Pageof 5
American Journal of Hematology|January 11, 2022
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register studyTorsten Dahlén, Gustaf Edgren, Per Ljungman, et al.Biochemical and Biophysical Research Communications|June 18, 2017
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemiaMonika Dolinska, Alexandre Piccini, Wan Man Wong, et al.Immunology|April 6, 2011
Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitroCamilla A Lindqvist, Lisa H Christiansson, Ingrid Thörn, et al.Blood|January 27, 2017
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CMLRebecca Warfvinge, Linda Geironson, Mikael N E Sommarin, et al.British Journal of Haematology|March 30, 2021
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Fredrik Sandin, Torsten Dahlén, et al.Scientific Reports|April 6, 2017
Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid LeukemiaLiza Löf, Linda Arngården, Ulla Olsson-Strömberg, et al.Therapeutic Drug Monitoring|December 24, 2015
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid LeukemiaKarin Skoglund, Johan Richter, Ulla Olsson-Strömberg, et al.Journal of Cancer Research and Clinical Oncology|March 25, 2017
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemiaHanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, et al.Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.Pageof 5